Psyence Biomedical LTD

Psyence Labs Ltd. has filed a Schedule 13D, revealing beneficial ownership of 1,146,159 common shares, representing 30.05% of Psyence Biomedical Ltd., acquired through a share-for-share exchange.

KAOS Capital Ltd. and Adam Arviv have reduced their beneficial ownership in Psyence Biomedical Ltd. to 4.91% due to an increase in outstanding shares, while expressing significant concerns about current management.

KAOS Capital Ltd. and its CEO Adam Arviv have disclosed a 16.77% beneficial ownership stake in Psyence Biomedical Ltd., citing the company's securities as undervalued.

Psyence Group Inc. has sold all of its common shares in Psyence Biomedical Ltd. between May 2, 2025, and May 9, 2025, and is no longer a beneficial owner of more than 5% of the Issuer's common shares.

Psyence Group Inc. has filed an amended Schedule 13D, revealing a 14.99% beneficial ownership stake in Psyence Biomedical Ltd., primarily through a business combination and the acquisition of Psyence Labs Ltd.

Jeffrey David Weiner has filed a Schedule 13G, reporting beneficial ownership of 59,750 shares, representing 2.61% of Psyence Biomedical Ltd.'s common stock.

Jeffrey David Weiner has reported a beneficial ownership of 5.07% of PSYENCE BIOMEDICAL LTD.'s Common Shares.

Harraden Circle Investments and its affiliated entities have filed an amendment to their Schedule 13G, reporting that they no longer beneficially own more than five percent of Psyence Biomedical Ltd.'s Class A Common Stock.

Hudson Bay Capital Management LP and Sander Gerber have filed an amended Schedule 13G, reporting a 4.99% beneficial ownership stake in Psyence Biomedical Ltd., primarily through warrants subject to a beneficial ownership blocker.

Harraden Circle Investments, LLC and its affiliated entities have filed an amended Schedule 13G, reporting a passive beneficial ownership of 5.32% of Psyence Biomedical Ltd.'s Class A Common Stock as of December 31, 2024.

Hudson Bay Capital Management LP and Sander Gerber have filed an amended Schedule 13G, revealing a combined beneficial ownership of 9.98% in Psyence Biomedical Ltd.'s common shares.